The mouse model of Parkinson disease (PD)

Sixty mice aged 7 weeks and weighing between 21–26 gm were obtained from Beijing Animal Institute, China. The mouse model of Parkinson Disease (PD) was developed using 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treatment. The mice were housed in plastic cages individually in controlled conditions at 23±2°C and given standard chow and freshwater. The mice were divided into six groups of ten mice: the negative control (NC) group; the MPTP and 0.5 mg/kg of 2-aminoquinoline, the 2AQ+MPTP (low dose) group; the MPTP and 1 mg/kg of 2-aminoquinoline, the 2AQ+MPTP (medium dose) group; and the MPTP and 2 mg/kg of 2-aminoquinoline, the 2AQ+MPTP (high dose) group.

PD in the mouse model was induced by intraperitoneal injection of 10 μl of 30 mg/kg of MPTP solution over five days. The 2-aminoquinoline was dissolved in normal saline and injected as a single dose, 40 minutes before injecting the MPTP. Motor deficits in the mice were measured after 8 h of MPTP injection one day before the development of the PD model, and on the first, fourth, seventh, and tenth day of the PD model. The experimental protocols were performed in accordance with the guidelines from the National Institutes of Health (NIH, Bethesda, MD, USA). Ethical approval for this study was given by the Animal Care and Use Committee, Changjiang University, Hubei Province, China.